Navigation Links
Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Date:2/9/2011

s about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended September 30, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Investor Relations Contact:Michael Aberman, M.D. Tel. +1 (914) 345-7799E-Mail: michael.aberman@regeneron.com Media Contact:Peter Dworkin, Tel. +1 (914) 345-7640E-Mail: peter.dworkin@regeneron.com
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regeneron Announces Presentation at the ISI Annual Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
3. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
4. Christine A. Poon Elected to Regeneron Board of Directors
5. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
6. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
7. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Regeneron Increases Size of Public Offering of Common Stock
9. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
10. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
11. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/12/2014)... The Security Analytics market is estimated to grow from ... at an expected CAGR of 9.7% for the period ... increasing number of security breaches, continued line of sophisticated ... organizations are enormous. Vendors in the security analytics market ... develop better and more secure systems. , There has ...
(Date:7/12/2014)... 2014 (HealthDay News) -- Burn injuries increase in the summer ... say burn experts. Among those most vulnerable to these seasonal ... vulnerable and often get burned by putting their hands on ... of the burn unit at Loyola University Medical Center in ... old adage of ,When you play with fire, you get ...
(Date:7/12/2014)... New York, New York (PRWEB) July 12, 2014 ... ) continue to move forward in U.S. courts, Bernstein ... that ties elevated metal ion levels to the failure ... the July 2nd issue of The Journal of Bone ... had received unilateral Articular Surface Replacement prostheses at ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
Breaking Medicine News(10 mins):Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, March ... cells differs significantly from region to region within a ... about the true potential of personalized cancer medicine. ... makeup to determine which drugs would work best in ...
... Reporter , WEDNESDAY, March 7 (HealthDay News) -- Researchers report ... immune system in patients who received kidney transplants, a process ... foreign organ instead of trying to reject it. There ... tiny number of patients. Also, the required procedure is expensive ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, March ... first to offer hope for children born with a rare ... die because they,re missing a rib cage to protect their ... the new medication is asfotase alfa. It works by replacing ...
... HealthDay Reporter , WEDNESDAY, March 7 (HealthDay News) -- ... paying for health care, a government report released Wednesday shows. ... that one in five families has difficulty paying medical bills, ... 10 can,t pay medical bills at all, according to the ...
... A team of researchers at Case Western Reserve University ... for the treatment of acute lymphoblastic leukemia (ALL). ALL ... in approximately 5,000 new cases each year in the ... that specifically focuses on the development of "theranostic" agents-- ...
... now for the annual meeting of the Pediatric Academic ... Boston April 28 to May 1, 2012. Journalists will ... original research in children,s health. The PAS meeting represents ... scientific discoveries, often before they appear in peer-reviewed journals. ...
Cached Medicine News:Health News:Is Cancer Outwitting 'Personalized Medicine'? 2Health News:Is Cancer Outwitting 'Personalized Medicine'? 3Health News:Transplant Procedure Creates 'Hybrid' Immune System to Combat Rejection 2Health News:Transplant Procedure Creates 'Hybrid' Immune System to Combat Rejection 3Health News:Experimental Drug Offers Hope for Rare Bone Disease: Study 2Health News:Experimental Drug Offers Hope for Rare Bone Disease: Study 3Health News:Many U.S. Families Struggle to Pay Medical Bills 2Health News:Researchers develop first 'theranostic' treatment for acute lymphoblastic leukemia (ALL) 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: